IMI €115m Call for proposals launch
18.12.2014 - IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.
The Brussels-based Innovative Medicines Initiative (IMI) has launched a 3rd Call for proposals to develop vaccines and medicines for the future. In addition to whooping cough (pertussis), the project’s topics include remote assessment of disease; diabetes; psychiatric disorders; vaccine manufacture and patient involvement in research.
Vaccines do exist for whopping cough, but a resurgence in the number of cases in certain countries is cause for concern. There are currently around 16 million cases and 195,000 deaths from whooping cough worldwide. IMI’s new project will make it possible to refine vaccination schedules to make them more effective and facilitate the development of new and improved vaccines.
‘It is unacceptable that a vaccine-preventable disease like whooping cough remains a leading cause of death for young people around the world,’ said Trevor Mundel, president of Global Health at the Bill & Melinda Gates Foundation. ‘We are excited to identify and develop more effective vaccines because when kids are healthier, communities and economies thrive.’
IMI’s vaccines project aims to develop and redefine a new approach to testing the quality of vaccines during the production process that will significantly reduce the need for animal testing. Vaccines have also been the focus of IMI's last Call for proposal aimed to address the Ebola crisis.
At the same as it launches its 3rd call, IMI will launch its 4th call for proposals with the aim of establishing a platform to coordinate activities relating to speeding up patient access to new medicines. “The IMI is committed to speeding up both medicines development and patient access to new medicines, especially in areas where treatments are lacking. I am confident that the resulting projects will contribute to making a real difference to patients’ lives,” said Irene Norstedt, IMI’s Acting Executive Director.